ARCT
ARCT
NASDAQ · Biotechnology

Arcturus Therapeutics Holdin

$8.31
-0.05 (-0.60%)
Financial Highlights (FY 2026)
Revenue
77.94M
Net Income
-62,504,453
Gross Margin
—
Profit Margin
-80.2%
Rev Growth
-26.4%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 42.6% 42.6%
Operating Margin -93.0% -83.7% -13.7% -14.9%
Profit Margin -80.2% -76.2% -16.2% -15.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 77.94M 105.94M 31.39M 23.67M
Gross Profit — — 13.39M 10.09M
Operating Income -72,455,409 -88,636,493 -4,296,176 -3,517,635
Net Income -62,504,453 -76,463,242 -5,088,256 -3,711,629
Gross Margin — — 42.6% 42.6%
Operating Margin -93.0% -83.7% -13.7% -14.9%
Profit Margin -80.2% -76.2% -16.2% -15.7%
Rev Growth -26.4% -26.4% +5.3% +9.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 42.41M 50.91M
Total Equity — — 148.93M 147.38M
D/E Ratio — — 0.28 0.35
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -69,584,700 -89,853,833 -7,015,778 -5,079,230
Free Cash Flow — — -5,929,972 -4,352,810